Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

NCT02335918 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT02335918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02335918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Lead sponsor
Celldex Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2015
Completion date
December 12, 2018
Enrollment
175 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (crc)-enrollment completed, glioblastoma (gbm) (phase ll only)-enrollment completed, ovarian carcinoma-enrollment completed, renal cell carcinoma (rcc) (phase ll only), squamous cell carcinoma of the head and neck (scchn)